Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is projected to have a firm value of $33 billion and a projected price objectiveof $130 per share. One of the main risks for the company is negative data for its various oncology drugs, and potential commercial risks and dilution risks. However, BioNTech has a strong lead in development with its commercialized product, and recent data has shown positive results for its oncology drugs, which could offset potential risks in the future. The company is also quickly transitioning to focus on its oncology pipeline, with a projected decline in COVID revenue over the next few years but a strong focus on advancing its oncology pipeline. The departure of the company's co-founders to start a new mRNA biotech also signals a dedicated focus on the company's oncology programs.

Bears say

BioNTech is a biotechnology company whose leadership team announced their departure to focus on a new venture, creating a ~20% decline in stock price and rattling investor confidence in the company's prospects. Clinical, regulatory, and competitive risks pose a threat to BioNTech's drug candidates, and any potential delays could significantly impact future revenue generation. The company has a diverse pipeline and potential value of $171 per common share, but with potential risks and uncertainties, the current valuation may not be justified.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.